Therapixel
therapixel.com
Computer Vision
Medical Imaging Systems
Medical AI
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Therapixel is a French medical imaging company founded in 2013 and based on the Cote d'Azur. Its MammoScreen software applies deep learning to mammograms to help radiologists detect breast cancer earlier. The product is approved in Europe and cleared by the United States Food and Drug Administration.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Omnes CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Second FDA okay for Therapixel's AI-based mammography tool
France's Therapixel has secured a second FDA approval for MammoScreen, its artificial intelligence-powered software for detecting cancerous lesions in mammogram images. MammoScreen was approved last year for use alongside conventional digital 2D mammograp
Read more
Report
MammoScreen Breast AI Adopted by Mayo Clinic for Radiology Use
Chicago/Paris, April 22, 2025 - Therapixel, the developer of MammoScreen, an AI-based breast cancer screening software, announces that Mayo Clinic has procured licenses for the use of MammoScreen across its radiology departments. The software provides rad
Read more
Report
Therapixel and Onsite Women's Health Announce Partnership to Deploy MammoScreen AI for Enhanced Breast Cancer Detection Across National Provider Network
PARIS and CHICAGO and NASHVILLE, April 3th, 2025 -Therapixel, creators of MammoScreen, a leading artificial intelligence (AI) solution for breast cancer screening, today announced a strategic partnership with Onsite Women's Health, one of the nation's lar
Read more
Report
Therapixel and Onsite Women's Health Announce Partnership to Deploy MammoScreen(R) AI for Enhanced Breast Cancer Detection Across National Provider Network
Read more
Report
Therapixel Announces Two New FDA Clearances for its Most Advanced Breast Cancer Screening AI Solution
Read more
Report
Therapixel Announces Two New FDA Clearances For Its Most Advanced Breast Cancer Screening AI Solution
Read more
Report
Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms
Paris and Nice, October 19th, 2022 - Therapixel, a French company specialized in the detection of breast cancer using artificial intelligence (AI), announces the start of a prospective clinical study to evaluate the contribution of AI in the second readin
Read more
Report
Therapixel releases a new version of MammoScreen that leverages prior exams for better accuracy
Paris, May 16th, 2022 - Therapixel, a company leading the use of AI-based software for women's health, announces it has released a new version of MammoScreen - 2D and 3D - capable of using prior mammograms into its analysis. By comparing a mammogram to th
Read more
Report
Therapixel announces close of 15 M€ series B financing to deploy MammoScreen 2D/3D
AI-powered reading aid for 2D & 3D screening mammography improves Radiologists' performance in cancer detection
Read more
Report
Therapixel announces close of 15 M€ series B financing to deploy MammoScreen 2D/3D
/PRNewswire/ -- Therapixel, designer and supplier of MammoScreen an Artificial Intelligence software reading aid for mammography, announces today fundraising...
Read more
Report
Show more news
People
Matthieu Leclerc-Chalvet
Directeur Général
Alexandre Loiseau
Président du conseil d’administration
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Nice
France
HQ
Financials
Total raised
$15M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2022 | $15M | Details |